Krystal Biotech (NASDAQ:KRYS) Shares Gap Up – What’s Next?

Krystal Biotech, Inc. (NASDAQ:KRYS) shares gapped up prior to trading on Wednesday . The stock had previously closed at $169.04, but opened at $176.59. Krystal Biotech shares last traded at $166.20, with a volume of 27,542 shares.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on KRYS. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Citigroup boosted their price target on Krystal Biotech from $204.00 to $206.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Chardan Capital reiterated a “buy” rating and issued a $212.00 price target on shares of Krystal Biotech in a research report on Thursday, December 12th. HC Wainwright reissued a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research note on Wednesday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $206.67.

Krystal Biotech Price Performance

The firm has a market cap of $4.85 billion, a price-to-earnings ratio of 95.50 and a beta of 0.80. The firm has a fifty day simple moving average of $181.01 and a two-hundred day simple moving average of $185.37.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to analyst estimates of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business’s quarterly revenue was up 879.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.67) earnings per share. Equities analysts anticipate that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. EFG Asset Management North America Corp. increased its position in shares of Krystal Biotech by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 12,555 shares of the company’s stock worth $2,308,000 after purchasing an additional 60 shares during the last quarter. Nisa Investment Advisors LLC increased its holdings in Krystal Biotech by 11.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 940 shares of the company’s stock valued at $173,000 after purchasing an additional 94 shares during the last quarter. Arizona State Retirement System raised its position in Krystal Biotech by 2.1% in the second quarter. Arizona State Retirement System now owns 5,147 shares of the company’s stock valued at $945,000 after purchasing an additional 108 shares during the period. Fiera Capital Corp lifted its stake in Krystal Biotech by 0.8% during the second quarter. Fiera Capital Corp now owns 16,208 shares of the company’s stock worth $2,976,000 after purchasing an additional 130 shares in the last quarter. Finally, KBC Group NV boosted its holdings in Krystal Biotech by 25.9% during the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock valued at $117,000 after acquiring an additional 132 shares during the period. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).